What we do Biocon Limited is India's largest integrated biopharmaceutical company focused on manufacturing biotechnology products, biosimilars, generics, and research services globally. |
Founded in 1,978 |
Market share Top 5 global biosimilar player with presence in 120+ countries and significant market shares in key biologics and insulin markets. |
Problem solved Addresses access to affordable and high-quality biotherapeutics and generics for chronic and critical diseases like diabetes, oncology, and autoimmune disorders. |
Top clients or who we serve Serves global pharmaceutical companies, healthcare providers, and patients; operates in B2B and B2C segments across emerging and developed markets. |
Key management Kiran Mazumdar-Shaw (Executive Chairperson), Siddharth Mittal (MD & CEO) |
Our journey and innovations From enzymes in 1979 to biosimilars and insulin analogs globally; pioneered India's first Clinical Research Organisation; expanded manufacturing and R&D footprint significantly. |
Where we operate India, USA, Europe, Malaysia, Middle East, Latin America, and other global markets. |
Top products or what we offer Biosimilars (Insulin Glargine, Trastuzumab, Bevacizumab), Generics, Contract Research Services, Emerging biosimilars and peptides. |
Top brands Semglee (bGlargine), Ogivri (bTrastuzumab), Fulphila (bPegfilgrastim), Basalog (Insulin), ALZUMAb (Itolizumab). |
Raw materials needed Biological substrates, fermentation media, synthetic chemicals, APIs, and cell culture materials. |
Raw materials supplier Multiple global suppliers and in-house manufacturing of key intermediates for quality and supply security. |
Recurring vs cyclical contribution High recurring revenue from biosimilars and research services; generics subject to pricing and patent cycles. |
Our industry position Leader in biosimilars with a robust consolidated global presence; among top contract research organizations worldwide. |
Financial highlights Consolidated revenue ₹164,699 million with 5% growth; PAT ₹10,133 million with expanding margins; strong balance sheet with improved debt profile. |
Geographical revenue split Revenue primarily from USA (43%), Europe (24%), India (6%), Malaysia and exports (27%). |
Order book Significant long-term contracts in biosimilars and contract research; growing pipeline of regulatory approvals. |
Whats driving growth Innovation in biosimilars and peptides, expanding generics portfolio, strategic global partnerships, and market expansion in advanced and emerging economies. |
Our future plans Consolidation of biosimilars and generics businesses, capacity expansions, new product launches in biosimilars and GLP-1s, enhancing manufacturing facilities. |
Our green promise Committed to ESG goals aligned with UN SDGs including sustainable manufacturing, renewable energy use, and community health initiatives. |
Our people and values 3,442 employees fostering diversity, inclusion, innovation, and ethical corporate governance with strong leadership development. |
Key challenges ahead Pricing pressures in generics, regulatory uncertainties, high competition in biosimilars, and supply chain disruptions. |
Interesting facts First Indian company approved by US FDA for lovastatin manufacturing; India’s largest integrated biotech park at Biocon Park, Bengaluru. |
Risks and strategy Mitigates risks via diversified portfolio, geographic spread, robust compliance, R&D investments, and strategic collaborations to sustain long-term growth. |
